NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has appointed Brent S. Rice as Chief Commercial Officer, bringing more than 25 years of commercial leadership experience in the biotechnology and pharmaceutical industry.
Rice most recently served as Senior Vice President and Global CCO, and Managing Director U.S. at Autolus Therapeutics Ltd., where he built the U.S. organization and oversaw the successful launch of its first commercial product. His career also includes leadership roles at Juno Therapeutics and nearly two decades at Amgen, where he advanced payer strategy, reimbursement, and product launches across multiple therapeutic areas.
“Brent brings a proven track record in launching novel therapies, building high-performing organizations, and leading strategic pipeline planning,” said Bing Yao, Chairman and CEO of ArriVent. “We believe his executive leadership experience will position us for success as firmonertinib nears potential approval and commercialization for EGFR mutant non-small cell lung cancer, and as we begin to unlock the potential of our ADC portfolio.”
Rice said he is eager to build a strong commercial foundation at ArriVent. “The company has a robust, science-driven pipeline that targets challenging and underserved areas in oncology,” he noted. “I look forward to working with the team to drive growth and ensure patients have access to these innovations.”
His appointment comes as ArriVent prepares for potential regulatory milestones and the transition toward commercialization.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.